Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
For patients with Graves' disease and lower antibody levels, shorter antithyroid drug treatment may work just as well. A new retrospective study found no significant difference in relapse rates between those treated for under a year versus the standard 12–18 months. Researchers say disease biology — not treatment length — may be the bigger factor in outcomes.
Current guidelines recommend 12–18 months of antithyroid drug (ATD) therapy for all Graves' disease patients, regardless of disease severity. But a new retrospective study published in Thyroid suggests that patients with lower thyrotropin receptor antibody (TRAb) levels — a marker of milder disease — may safely stop treatment in under a year without a higher risk of relapse.
The study followed 369 adults with new-onset Graves' disease and TRAb levels between 1.8 and 10 U/L. About 36% received ATDs for less than a year, while 64% were treated for the standard 12–18 months. Relapse rates at one year were nearly identical across both groups, and sensitivity analysis showed no difference in later relapse either.
By the Numbers:
Why it matters: A one-size-fits-all approach to ATD therapy may be leaving some patients on medication longer than necessary. Personalizing treatment duration based on TRAb levels could reduce unnecessary drug exposure — though researchers stress a randomized noninferiority trial is still needed to confirm these findings.
